Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target

Benzinga Newsdesk www.benzinga.com Negative 64.7%

Neg 64.7% Neu 0% Pos 0%

Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.